Newron Pharmaceuticals S.p.A. (SWX:NWRN)
Switzerland
· Delayed Price · Currency is CHF 14.80
-0.28 (-1.86%)
Apr 29, 2026, 11:05 AM CET
Newron Pharmaceuticals Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 16.4 | 51.39 | 6.79 | 5.95 | 5.76 | Upgrade
|
| Other Revenue | 2.73 | - | 2.26 | 0.14 | - | Upgrade
|
| Revenue | 19.13 | 51.39 | 9.06 | 6.09 | 5.76 | Upgrade
|
| Revenue Growth (YoY) | -62.78% | 467.41% | 48.62% | 5.76% | 9.59% | Upgrade
|
| Gross Profit | 19.13 | 51.39 | 9.06 | 6.09 | 5.76 | Upgrade
|
| Selling, General & Admin | 8.7 | 11.58 | 7.53 | 7.39 | 7.39 | Upgrade
|
| Research & Development | 15.12 | 13.64 | 13.15 | 12.01 | 10.73 | Upgrade
|
| Operating Expenses | 23.82 | 25.22 | 20.69 | 19.4 | 18.12 | Upgrade
|
| Operating Income | -4.7 | 26.17 | -11.63 | -13.3 | -12.36 | Upgrade
|
| Interest Expense | -4.4 | -4.35 | -4.17 | -3.95 | -2.92 | Upgrade
|
| Interest & Investment Income | 0.54 | 0.14 | 0.18 | 0.06 | 0.05 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.08 | -0.1 | -0.07 | 0.12 | 0.2 | Upgrade
|
| Other Non Operating Income (Expenses) | -3.72 | -0.47 | -0.51 | -0.4 | 0.13 | Upgrade
|
| EBT Excluding Unusual Items | -12.35 | 21.39 | -16.2 | -17.47 | -14.88 | Upgrade
|
| Pretax Income | -12.35 | 21.39 | -16.2 | -17.47 | -14.88 | Upgrade
|
| Income Tax Expense | 0.89 | 5.55 | 0.02 | 0.02 | 0.02 | Upgrade
|
| Net Income | -13.24 | 15.84 | -16.22 | -17.49 | -14.9 | Upgrade
|
| Net Income to Common | -13.24 | 15.84 | -16.22 | -17.49 | -14.9 | Upgrade
|
| Shares Outstanding (Basic) | 20 | 19 | 18 | 18 | 18 | Upgrade
|
| Shares Outstanding (Diluted) | 20 | 21 | 18 | 18 | 18 | Upgrade
|
| Shares Change (YoY) | -2.98% | 15.30% | - | - | - | Upgrade
|
| EPS (Basic) | -0.66 | 0.85 | -0.91 | -0.98 | -0.84 | Upgrade
|
| EPS (Diluted) | -0.66 | 0.77 | -0.91 | -0.98 | -0.84 | Upgrade
|
| Free Cash Flow | 32.3 | -17.63 | -10.15 | -11.11 | -11.47 | Upgrade
|
| Free Cash Flow Per Share | 1.62 | -0.86 | -0.57 | -0.62 | -0.64 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -24.56% | 50.93% | -128.40% | -218.28% | -214.46% | Upgrade
|
| Profit Margin | -69.22% | 30.83% | -179.13% | -287.05% | -258.61% | Upgrade
|
| Free Cash Flow Margin | 168.89% | -34.30% | -112.08% | -182.31% | -198.98% | Upgrade
|
| EBITDA | -4.68 | 26.2 | -11.49 | -13.27 | -12.31 | Upgrade
|
| EBITDA Margin | -24.45% | 50.98% | -126.89% | -217.67% | -213.64% | Upgrade
|
| D&A For EBITDA | 0.02 | 0.02 | 0.14 | 0.04 | 0.05 | Upgrade
|
| EBIT | -4.7 | 26.17 | -11.63 | -13.3 | -12.36 | Upgrade
|
| EBIT Margin | -24.56% | 50.93% | -128.40% | -218.28% | -214.46% | Upgrade
|
| Effective Tax Rate | - | 25.95% | - | - | - | Upgrade
|
| Revenue as Reported | 19.13 | 51.39 | 9.06 | 6.09 | 5.76 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.